CYP2B19 Inhibitors
CYP2B19 inhibitors are a specialized class of chemical compounds that specifically target and inhibit the activity of the CYP2B19 enzyme, a member of the cytochrome P450 superfamily. CYP2B19, like other enzymes in this family, is involved in the oxidative metabolism of various substrates, including both endogenous molecules such as steroids, fatty acids, and certain vitamins, as well as exogenous compounds like drugs and environmental toxins. The enzyme's primary function is to catalyze the monooxygenation of these substrates, a biochemical process that typically results in the insertion of an oxygen atom into the substrate, making it more water-soluble and thereby facilitating its further metabolism or excretion from the body. This oxidative process is a crucial step in the detoxification and biotransformation pathways that maintain cellular and systemic homeostasis, particularly within the liver where cytochrome P450 enzymes are most abundantly expressed.
Inhibitors of CYP2B19 are typically small molecules that are designed to bind to the enzyme's active site, thereby preventing it from interacting with its natural substrates. These inhibitors may work by occupying the substrate-binding pocket, blocking the access of substrates to the catalytic site, or by inducing conformational changes that reduce the enzyme's catalytic efficiency. The development of CYP2B19 inhibitors often requires a thorough understanding of the enzyme's three-dimensional structure, especially the regions involved in substrate recognition and catalysis. By inhibiting CYP2B19, researchers can study its specific role in various metabolic processes, shedding light on how this enzyme contributes to the broader metabolic network governed by the cytochrome P450 superfamily. The investigation of CYP2B19 inhibitors provides valuable insights into the enzyme's substrate specificity, its role in the metabolism of particular compounds, and its interactions with other enzymes within the cytochrome P450 family. This research enhances our understanding of the diverse functions of cytochrome P450 enzymes and their importance in maintaining the balance of metabolic processes within biological systems.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Fluconazole | 86386-73-4 | sc-205698 sc-205698A | 500 mg 1 g | $54.00 $84.00 | 14 | |
Fluconazole, a direct inhibitor of CYP2B19, disrupts its heme binding and monooxygenase activities. This interference extends to xenobiotic catabolic processes, suggesting a role in cellular detoxification mechanisms and response modulation. | ||||||
Ketoconazole | 65277-42-1 | sc-200496 sc-200496A | 50 mg 500 mg | $63.00 $265.00 | 21 | |
Ketoconazole directly inhibits CYP2B19, influencing its heme binding and monooxygenase activities. This modulation extends to steroid metabolic processes, suggesting a potential role in regulating steroid biosynthesis. | ||||||
Efavirenz | 154598-52-4 | sc-207612 | 10 mg | $171.00 | 3 | |
Efavirenz, a direct inhibitor of CYP2B19, impacts its heme binding and monooxygenase activities. This interference extends to xenobiotic catabolic processes, suggesting a potential role in cellular detoxification mechanisms and response regulation. | ||||||
Miconazole | 22916-47-8 | sc-204806 sc-204806A | 1 g 5 g | $66.00 $160.00 | 2 | |
Miconazole, as a direct inhibitor of CYP2B19, disrupts its heme binding and monooxygenase activities. This interference extends to xenobiotic catabolic processes, suggesting a role in cellular detoxification mechanisms and response modulation. | ||||||
Clarithromycin | 81103-11-9 | sc-205634 sc-205634A | 100 mg 250 mg | $77.00 $122.00 | 1 | |
Clarithromycin serves as a direct inhibitor of CYP2B19, influencing its heme binding and monooxygenase activities. This modulation extends to xenobiotic catabolic processes, suggesting a potential role in cellular detoxification mechanisms and response regulation. | ||||||
Ritonavir | 155213-67-5 | sc-208310 | 10 mg | $124.00 | 7 | |
Ritonavir acts as a direct inhibitor of CYP2B19, impacting its heme binding and monooxygenase activities. This interference extends to xenobiotic catabolic processes, suggesting a potential role in cellular detoxification mechanisms and response modulation. | ||||||
FK-506 | 104987-11-3 | sc-24649 sc-24649A | 5 mg 10 mg | $78.00 $151.00 | 9 | |
Tacrolimus inhibits CYP2B19 directly, influencing its heme binding and monooxygenase activities. This interference extends to xenobiotic catabolic processes, suggesting a potential role in cellular detoxification mechanisms and response modulation. | ||||||
Terbinafine | 91161-71-6 | sc-338609 | 100 mg | $560.00 | 1 | |
Terbinafine, a direct inhibitor of CYP2B19, disrupts its heme binding and monooxygenase activities. This interference extends to xenobiotic catabolic processes, suggesting a role in cellular detoxification mechanisms and response modulation. | ||||||
Fluoxetine | 54910-89-3 | sc-279166 | 500 mg | $318.00 | 9 | |
Fluoxetine serves as a direct inhibitor of CYP2B19, influencing its heme binding and monooxygenase activities. This modulation extends to xenobiotic catabolic processes, suggesting a potential role in cellular detoxification mechanisms and response regulation. | ||||||
Disulfiram | 97-77-8 | sc-205654 sc-205654A | 50 g 100 g | $53.00 $89.00 | 7 | |
Disulfiram acts as a direct inhibitor of CYP2B19, interfering with its heme binding and monooxygenase activities. This modulation extends to xenobiotic catabolic processes, suggesting a role in cellular detoxification mechanisms and response modulation. | ||||||